Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in DAPA-HF
Kieran F. Docherty(University of Glasgow), John J.V. McMurray(Western Infirmary)
Cited by 13
Related Papers
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
|The Lancet Diabetes & Endocrinology|2019|1.6k
Economics of Chronic Heart Failure
|European Journal of Heart Failure|2001|404